Videos

Pharmacists can help optimize TKI therapy in CML through education, adherence support, toxicity monitoring, and collaboration with care teams.

Bispecific antibodies are reshaping multiple myeloma care through improved safety and expanded outpatient use.

Integrated health plan–provider collaboration enables pharmacists to drive proactive diabetes management, improve adherence, and expand access to CGM and lifestyle support.

Combining AI-driven insights with human-first outreach can overcome the emotional and behavioral barriers driving specialty medication non-adherence.

Clinicians compare PD-1 immunotherapies in endometrial cancer, weighing trial differences, progression-free survival, response rates, toxicity, and long-term quality of life.

Overall survival guides first-line endometrial cancer choices, as RUBY shows mature dostarlimab benefit while pembrolizumab OS awaits.

This week's episode highlights a new executive order signed by President Trump, new expanded FDA approvals, and a conference roundup.

Rapport Therapeutics' RAP-219 achieved seizure freedom in 24% of patients with drug-resistant focal epilepsy over 8 weeks in a phase 2 trial.

A cognitive neurologist outlines the current Alzheimer disease treatment landscape.

How community oncology practices are expanding access to innovative therapies while navigating reimbursement and care delivery challenges.

Pharmacists must remain in a constant state of readiness by implementing structured shortage management plans and guiding patients through access challenges as supply disruptions persist.

AI is delivering immediate clinical value in neurology—from ambient scribes and clinical decision support to trial recruitment and medical education.

A Harvard population health researcher presents findings linking adolescent food insecurity to a cluster of brain health risk factors.

Pharmacy Times interviews Robert R. Jeng, MD, on how the gut microbiome may influence CAR T-cell therapy response, toxicity, and persistence, as well as the challenges and future potential of microbiome-based interventions in improving patient outcomes.

Pharmacy Times interviews Kamel Lahouel, PhD, and Cristian Tomasetti, PhD, on the challenges of predicting MHC class II peptide binding and how combining structural and sequence-based models can improve accuracy while addressing key limitations.

Pharmacy Times interviews Lorin Fisher, PhD, BCACP, on her presentation, “Gabapentin for Pain Management: Well Done or Overdone?,” presented at the SPPCP conference. Fisher discusses the evolving role of gabapentin in pain care, highlighting where evidence supports its use, where it may be overprescribed, and key considerations for pharmacists in optimizing safe and appropriate therapy.

Cannabidiol may have broader applicability across genetic developmental and epileptic encephalopathies (DEEs).

Bocunebart, a novel anti-PACAP antibody, targets a distinct neurological pathway from existing CGRP therapies.

Pharmacists manage QTc monitoring with ribociclib, confirm QTcF, assess interactions, hold and dose-reduce therapy, and guide CDK4/6 switches for toxicity or cost.

Learn how pharmacists spot and manage ribociclib QTc prolongation, handle drug interactions, and switch CDK4/6 inhibitors for safety and cost.

Pharmacy Times interviewed Kimlin Ashing and Narissa Nonzee about their work examining how housing status, race, and ethnicity drive cancer screening disparities.

Enrique Velazquez Villarreal, MD, PhD, used a conversational AI platform to unify microbiome, genomic, clinical, and social determinants of health data for colorectal cancer research.

Geopolitical conflict could affect drug manufacturing and global trade routes, with potential downstream impacts on medication costs and availability.

Cemdisiran’s RNA-targeting mechanism is a compelling new option in the generalized myasthenia gravis treatment landscape.

Biological sex and societal gender factors independently—and differently—influence TBI mortality, discharge destination, and long-term cognitive recovery.

Despite the availability of 4 FDA-approved biologics, the majority of NMOSD patients remain on off-label rituximab.

The menopausal transition alters brain circuitry and estrogen signaling in ways that may elevate risk for Alzheimer disease.

Sex and gender differences remain critically underrepresented in traumatic brain injury clinical guidelines.